Background There is not a prevailing consensus on appropriate antibiotic choice, route, and duration in the treatment of bacterial pleural empyema after appropriate source control. Professional society guidelines note the lack of comparative trials with which to guide recommendations. We assessed clinical outcomes in the treatment of known and suspected empyema based upon three aspects of antibiotic use: (1) total duration, (2) duration of intravenous (IV) antibiotics, and (3) duration of anti-anaerobic antibiotics. Methods We performed a hypothesis-generating retrospective chart review analysis of 355 adult inpatients who had pleural drainage, via either chest tube or surgical intervention, for known or suspected empyema. The primary outcome variable was clinician assessment of resolution or lack thereof. The secondary outcomes were death within 90 days, hospital readmission within 30 days for empyema, and all-cause hospital readmission within 30 days. Mann-Whitney U test was used to compare outcomes with regard to these variables. Results None of the independent variables was significantly associated with a difference in clinical resolution rate despite trends for total antibiotic duration and anti-anaerobic antibiotic duration. None of the independent variables was associated with mortality. Longer total antibiotic duration was associated with lower readmission rate for empyema (median 17 [interquartile range 11–28] antibiotic days in non-readmission group vs. 13 [6-15] days in readmission group), with a non-significant trend for all-cause readmission rate (17 [11–28] days vs. 14 [9–21] days). IV antibiotic duration was not associated with a difference in any of the defined outcomes. Longer duration of anti-anaerobic antibiotics was associated with both lower all-cause readmission (8.5 [0–17] vs. 2 [0–11]) and lower readmission rate for empyema (8 [0–17] vs. 2 [0–3]). Conclusion Our data support the premise that routine use of anti-anaerobic antibiotics is indicated in the treatment of pleural empyema. However, our study casts doubt on the benefits of extended IV rather than oral antibiotics in the treatment of empyema. This represents a target for future investigation that could potentially limit complications associated with the excessive use of IV antibiotics.
Background There is not a prevailing consensus on appropriate antibiotic choice, route, and duration in the treatment of bacterial pleural empyema after appropriate source control. Professional society guidelines identify a wide range of antibiotic durations, and generally recommend an antibiotic with broad-spectrum activity against anaerobes (e.g. clindamycin, metronidazole, carbapenem, or penicillin/beta-lactamase inhibitor combination), while noting the lack of comparative trials with which to guide recommendations. Methods We performed a hypothesis-generating retrospective chart review analysis of clinical outcomes in 355 adult inpatients who had pleural drainage, via either chest tube or surgical intervention, for known or suspected empyema. The aims of the investigation were to compare clinical outcomes with regard to 1) the use of antibiotics with broad activity against anaerobes, 2) total antibiotic duration, and 3) IV antibiotic duration. Mann-Whitney U test with Bonferroni multiplicity adjustment was used to compare outcomes with regard to these variables. Results A longer course of an anti-anaerobic antibiotic was associated with both lower 30-day readmission rates for empyema (11.9 ± 13.8 antibiotic days in non-readmission group, n = 321 vs 2.2 ± 2.7 days in readmission group, n = 17, p-value 0.003) and lower all-cause 30-day readmission (12.3 ± 14.1 in non-readmission group, n = 290 vs 6.1 ± 7.9 in readmission group, n = 49, p-value 0.003). Longer total antibiotic duration was associated with lower empyema-specific 30-day readmission rates (21.5 ± 20.1 vs 12.4 ± 8.2, p-value 0.010), with a non-significant trend towards lower all-cause 30-day readmission (22.1 ± 20.9 vs 15.0 ± 8.3). IV antibiotic duration was not associated with a difference in 30-day readmission (data not shown). Conclusion Our data support the premise that routine use of anti-anaerobic antibiotics is indicated in the treatment of pleural empyema. However, our study casts doubt on the benefits of extended IV rather than oral antibiotics in the treatment of empyema. This represents a target for future investigation with the aim of limiting complications associated with the excessive use of IV antibiotics. Disclosures All Authors: No reported disclosures.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.